Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Vericiguat

Drug and asset intelligence for Vericiguat with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Torrent Pharmaceuticals →

Recent signals(3)

RegulatoryAugust 17, 2026

FDA submission status update for Vericiguat by Changzhou Pharmaceutical Factory

The FDA has accepted the ANDA220264 application for Vericiguat, submitted by Changzhou Pharmaceutical Factory, which is currently undergoing standard review. Vericiguat, a soluble guanylate cyclase stimulator, is aimed at treating heart failure and is entering a market with established therapies.

RegulatoryJuly 28, 2026

FDA Submission Overview for Vericiguat by Torrent Pharmaceuticals

Torrent Pharmaceuticals has submitted an original application for Vericiguat (ANDA220221) to the FDA, currently under standard review.

July 5, 2026

Torrent Pharmaceuticals submits ANDA for Vericiguat

Torrent Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) for Vericiguat.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Vericiguat

July 5, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiology · Heart Failure →

Heart Failure →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.